| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Institute for Neurodegenerative Diseases, University of California, 513 Parnassus Ave, San Francisco, CA 94143, USA
2 Department of Neurology, University of California, 513 Parnassus Ave, San Francisco, CA 94143, USA
3 Department of Pathology, University of California, 513 Parnassus Ave, San Francisco, CA 94143, USA
4 Department of Biochemistry and Biophysics, University of California, 513 Parnassus Ave, San Francisco, CA 94143, USA
Correspondence
Stanley B. Prusiner
stanley{at}ind.ucsf.edu
The clearance of prions from the brain was investigated in bigenic mice designated Tg(tTA : PrP+/0)3, in which expression of the cellular prion protein (PrPC) was regulated by oral doxycycline administration. With suppression of PrPC expression, the incubation time for RML prions was prolonged almost threefold from 
150 to 430 days. To determine the clearance rate of disease-causing PrPSc, bigenic mice were given oral doxycycline beginning 98 days after inoculation with RML prions and sacrificed at various time points over the subsequent 56 days. The half-life (t1/2) for PrPSc was 1·5 days in mouse brain, in reasonable agreement with the apparent t1/2 of 30 h that was determined in a separate study for scrapie-infected mouse neuroblastoma (ScN2a) cells in culture. Both protease-sensitive and -resistant conformers of PrPSc were cleared at the same rate. The t1/2 value for PrPC clearance from brain was 18 h, which was considerably longer than the t1/2 of 5 h found in ScN2a cells. The capability of the brain to clear prions raises the possibility that PrPSc is normally made at low levels and continually cleared, and that PrPSc may have a function in cellular metabolism. Moreover, these bigenic mice make it possible to determine both components of PrPSc accumulation, i.e. the rates of formation and clearance, for various strains of prions exhibiting different incubation times.
Supplementary material is available in JGV Online.
Present address: Neurochem Inc., 275 boul. Armand-Frappier, Laval, Quebec, Canada H7V 4A7.
This article has been cited by other articles:
|
|
 |
|
  J. Stohr, N. Weinmann, H. Wille, T. Kaimann, L. Nagel-Steger, E. Birkmann, G. Panza, S. B. Prusiner, M. Eigen, and D. Riesner Mechanisms of prion protein assembly into amyloid PNAS, February 19, 2008; 105(7): 2409 - 2414. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Seabury, C. A. Gill, J. W. Templeton, J. B. Dyar, J. N. Derr, D. L. Adelson, E. Owens, D. S. Davis, D. C. Kraemer, and J. E. Womack Molecular Characterization of the Rocky Mountain Elk (Cervus elaphus nelsoni) PRNP Putative Promoter J. Hered., November 21, 2007; (2007) esm091v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Deleault, B. T. Harris, J. R. Rees, and S. Supattapone From the Cover: Formation of native prions from minimal components in vitro PNAS, June 5, 2007; 104(23): 9741 - 9746. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Legname, H.-O. B. Nguyen, D. Peretz, F. E. Cohen, S. J. DeArmond, and S. B. Prusiner Continuum of prion protein structures enciphers a multitude of prion isolate-specified phenotypes PNAS, December 12, 2006; 103(50): 19105 - 19110. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Yuan, X. Xiao, J. McGeehan, Z. Dong, I. Cali, H. Fujioka, Q. Kong, G. Kneale, P. Gambetti, and W.-Q. Zou Insoluble Aggregates and Protease-resistant Conformers of Prion Protein in Uninfected Human Brains J. Biol. Chem., November 17, 2006; 281(46): 34848 - 34858. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
